Cytocell operations move to Cambridge Science Park

Growth of the Oxford Gene Technology's brand has lead to an investment in expanding the production capacity to meet demand

Oxford Gene Technology (OGT) has upgraded its Cytocell operations with a move to a larger facility on the Cambridge Science Park. OGT’s fluorescence in situ hybridisation (FISH) probe brand will be expanding due to the current sales volume and its predicted growth.

Over recent months, the molecular genetics company has been expanding the direct sales of Cytocell products in Europe and Asia. Staff numbers across the organisation are increasing and a larger space is needed for manufacturing and logistics facilities to match the increased volume of product manufacture and shipment.

The new facility will have approximately three times the floor space of Cytocell’s current premises, with the capacity to deliver a significant increase in output as the business continues to grow. OGT also plans to create a training and demonstration facility in the new premises to host its customers.

The investment in the growth of the brand comes from OGT’s parent company, Sysmex.

Kenji Tsujimoto, Executive VP of Technology Strategy at Sysmex, said: ‘This significant investment in the company is testament to our confidence and desire to further develop OGT’s brands alongside our portfolios’.

In addition to investing in OGT’s Cytocell brand, Sysmex is considering creating a global R&D facility at the premises, to evaluate new technologies and pursue collaborations with key opinion leaders.

John Anson, CEO of OGT, said: “Our ever-growing cooperation with Sysmex delivers the benefits of being part of a larger organisation to our customers, providing them with enhanced services and support.’

OGT anticipates the new facility to be fully operational by May 2019.

Companies